At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
Abacavir sulfate +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Open-Label Study to Evaluate the Safety and Effectiveness of Two Antiretroviral Therapeutic Strategies: A Dual PI-Based HAART Regimen Versus a Multi-NRTI ART Regimen, in ART-Experienced Children and Youth Who Have Experienced Virologic Failure
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jan 26, 2005·Updated Nov 1, 2021
In Brief
A Phase 2 clinical trial evaluating Abacavir sulfate, Emtricitabine, and 5 other interventions for HIV Infections. Completed, enrolled 6 participants across 4 sites.
Detailed Summary
HIV infected children and adolescents who have taken many anti-HIV drugs may have limited treatment options and are at high risk for progressing to AIDS. The purpose of this study is to determine whether an anti-HIV treatment regimen of 2 protease inhibitors (PIs) and 2 nucleoside reverse transcriptase inhibitors (NRTIs) is more effective than a regimen of 4 NRTIs in treatment-experienced children and adolescents who have failed previous anti-HIV treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2005
Study CompletionMay 2007
TodayJul 2026
First PostedJan 26, 2005
Study CompletionMay 1, 2007
TodayJul 2, 2026
Posted 21.4 years ago
Interventions
Abacavir sulfatedrug
Emtricitabinedrug
Lamivudinedrug
Lopinavir/ritonavirdrug
Saquinavirdrug
Tenofovir disoproxil fumaratedrug
Zidovudinedrug